Clinical Studies in Patients with Solid Tumors using a Second-Generation Antisense Oligonucleotide (GEM®231) Targeted against Protein Kinase A Type I

Chemical Compounds

• Taxane 63%
• Antisense Oligonucleotide 62%
• Activated Partial Thromboplastin Time 42%
• Paclitaxel 35%
• Antitumor 27%
• Safety 25%
• Peak Plasma Concentration 20%
• Camptothecin 19%
• Western Blotting 18%
• Protein 18%
• Pump 14%
• Dose 11%
• Pharmacokinetics 11%
• Additive 9%
• Chemical Transformation 9%
• Plasma 9%

Medicine & Life Sciences

• GEM231 100%
• Antisense Oligonucleotides 51%
• Cyclic AMP-Dependent Protein Kinases 46%
• Clinical Studies 30%
• Neoplasms 14%
• Camptothecin 11%
• taxane 11%
• Partial Thromboplastin Time 10%
• Docetaxel 9%
• Transaminases 9%
• Paclitaxel 9%
• Serum 8%
• Appointments and Schedules 7%
• Taxoids 5%
• Esophagitis 5%
• Drug Therapy 5%
• Safety 5%
• Enzyme Assays 5%
• Therapeutics 4%
• Antineoplastic Agents 4%
• Heterografts 4%
• Fatigue 3%
• Lung Neoplasms 3%
• Pharmacokinetics 3%
• Western Blotting 3%
• Cell Proliferation 2%
• Hemorrhage 2%

Arts & Humanities

• Protein 53%
• Therapy 23%
• Dose 22%
• Plasma 20%
• Chemotherapy 19%
• Safety 13%
• Lung Cancer 11%
• Toxicity 10%
• Cancer Patients 10%
• Cancer 8%
• Fatigue 8%
• Elevation 8%
• Progression 7%
• Blood 5%
• Cells 5%
• Interaction 4%